FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137487130> ?p ?o ?g. }

• W2137487130 abstract "Healthy farm animals have been found to act as a reservoir of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli). Therefore, the objective of the study was to determine the input of antimicrobial active ceftiofur metabolites in the stable via faeces and urine after intramuscular administration of the drug to pigs and the elucidation of the Escherichia coli ESBL resistance pattern of treated and untreated pigs housed in the same barn during therapy.For determination of the minimal inhibitory concentration (MIC) the method of microdilutionaccording to the recommended procedure of the Clinical and Laboratory Standards Institute was used. Inaddition to that, a qualitative determination was performed by agar dilution. Unsusceptible E. coli speciesselected via agar dilution with cefotaxime were confirmed by MALDI-TOF and ESBL encoding genes wereidentified by PCR. The amounts of ceftiofur measured as desfuroylceftiofur (DFC) in the different probes (plasma, urine, faeces and dust) were analysed by UPLC-MS/MS.In a first experiment two groups of pigs (6 animals per group) were housed in the same barn in two separated boxes. One group (group B) were treated with ceftiofur according to the licence (3 mg/kg administered intramuscularly (i.m.) on three consecutive days, day 1-3). During a second treatment period (day 29-31) an increased rate of ESBL resistant E. coli was detectable in these treated pigs and in the air of the stable. Moreover, the second group of animals (group A) formerly untreated but housed for the whole period in the same stable as the treated animals revealed increased resistance rates during their first treatment (day 45-47) with ceftiofur. In order to investigate the environmental input of ceftiofur during therapy and to simulate oral uptake of ceftiofur residues from the air of the stable a second set of experiments were performed. Pigs (6 animals) were treated with an interval of 2 weeks for 3 days with different doses of ceftiofur (3 mg/kg, 1 mg/kg and 0.3 mg/kg i.m.) as well as with 3 mg/kg per os) and the renal and biliary excretion of ceftiofur as its active metabolite were measured in comparison to the plasma levels. In addition to that, probes of the sedimentation dust and the air of the stable were analysed for drug residues.The present study shows that treatment of several animals in a stable with ceftiofur influences the resistance pattern of intestinal Escherichia coli of the treated as well as untreated animals housed in the same stable. During therapy with the drug which was administered by injection according to the licence we detected nameable amounts of ceftiofur and its active metabolites in the dust and air of the stable." @default.
• W2137487130 created "2016-06-24" @default.
• W2137487130 creator A5013990738 @default.
• W2137487130 creator A5014709254 @default.
• W2137487130 creator A5015296467 @default.
• W2137487130 creator A5024065527 @default.
• W2137487130 creator A5056560408 @default.
• W2137487130 creator A5076028970 @default.
• W2137487130 creator A5076313739 @default.
• W2137487130 creator A5087570617 @default.
• W2137487130 creator A5091389506 @default.
• W2137487130 date "2015-10-15" @default.
• W2137487130 modified "2023-09-25" @default.
• W2137487130 title "Effects of ceftiofur treatment on the susceptibility of commensal porcine E.coli – comparison between treated and untreated animals housed in the same stable" @default.
• W2137487130 cites W1524165148 @default.
• W2137487130 cites W1854937501 @default.
• W2137487130 cites W1965403055 @default.
• W2137487130 cites W1966706514 @default.
• W2137487130 cites W1987981914 @default.
• W2137487130 cites W1989985563 @default.
• W2137487130 cites W1992336491 @default.
• W2137487130 cites W1996608843 @default.
• W2137487130 cites W1997152162 @default.
• W2137487130 cites W1999092372 @default.
• W2137487130 cites W2012672361 @default.
• W2137487130 cites W2013452629 @default.
• W2137487130 cites W2016790836 @default.
• W2137487130 cites W2018046239 @default.
• W2137487130 cites W2019742352 @default.
• W2137487130 cites W2025772409 @default.
• W2137487130 cites W2049702963 @default.
• W2137487130 cites W2061606889 @default.
• W2137487130 cites W2062549291 @default.
• W2137487130 cites W2069215373 @default.
• W2137487130 cites W2073703928 @default.
• W2137487130 cites W2074604023 @default.
• W2137487130 cites W2078340635 @default.
• W2137487130 cites W2086141310 @default.
• W2137487130 cites W2098795058 @default.
• W2137487130 cites W2108864681 @default.
• W2137487130 cites W2111816131 @default.
• W2137487130 cites W2113166746 @default.
• W2137487130 cites W2121444224 @default.
• W2137487130 cites W2127072069 @default.
• W2137487130 cites W2130120128 @default.
• W2137487130 cites W2132743040 @default.
• W2137487130 cites W2136279468 @default.
• W2137487130 cites W2142375377 @default.
• W2137487130 cites W2151939284 @default.
• W2137487130 cites W2158111262 @default.
• W2137487130 cites W2397733594 @default.
• W2137487130 cites W2411720871 @default.
• W2137487130 cites W2412845429 @default.
• W2137487130 cites W2431589988 @default.
• W2137487130 doi "https://doi.org/10.1186/s12917-015-0578-3" @default.
• W2137487130 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4608134" @default.
• W2137487130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26472561" @default.
• W2137487130 hasPublicationYear "2015" @default.
• W2137487130 type Work @default.
• W2137487130 sameAs 2137487130 @default.
• W2137487130 citedByCount "12" @default.
• W2137487130 countsByYear W21374871302016 @default.
• W2137487130 countsByYear W21374871302017 @default.
• W2137487130 countsByYear W21374871302018 @default.
• W2137487130 countsByYear W21374871302021 @default.
• W2137487130 countsByYear W21374871302022 @default.
• W2137487130 crossrefType "journal-article" @default.
• W2137487130 hasAuthorship W2137487130A5013990738 @default.
• W2137487130 hasAuthorship W2137487130A5014709254 @default.
• W2137487130 hasAuthorship W2137487130A5015296467 @default.
• W2137487130 hasAuthorship W2137487130A5024065527 @default.
• W2137487130 hasAuthorship W2137487130A5056560408 @default.
• W2137487130 hasAuthorship W2137487130A5076028970 @default.
• W2137487130 hasAuthorship W2137487130A5076313739 @default.
• W2137487130 hasAuthorship W2137487130A5087570617 @default.
• W2137487130 hasAuthorship W2137487130A5091389506 @default.
• W2137487130 hasBestOaLocation W21374871301 @default.
• W2137487130 hasConcept C104317684 @default.
• W2137487130 hasConcept C126322002 @default.
• W2137487130 hasConcept C127413603 @default.
• W2137487130 hasConcept C140793950 @default.
• W2137487130 hasConcept C147176958 @default.
• W2137487130 hasConcept C176947019 @default.
• W2137487130 hasConcept C2778719061 @default.
• W2137487130 hasConcept C2780026642 @default.
• W2137487130 hasConcept C2780122547 @default.
• W2137487130 hasConcept C2780883654 @default.
• W2137487130 hasConcept C42972112 @default.
• W2137487130 hasConcept C4937899 @default.
• W2137487130 hasConcept C501593827 @default.
• W2137487130 hasConcept C547475151 @default.
• W2137487130 hasConcept C55493867 @default.
• W2137487130 hasConcept C61716771 @default.
• W2137487130 hasConcept C64778159 @default.
• W2137487130 hasConcept C71924100 @default.
• W2137487130 hasConcept C86803240 @default.
• W2137487130 hasConcept C89423630 @default.
• W2137487130 hasConceptScore W2137487130C104317684 @default.
• W2137487130 hasConceptScore W2137487130C126322002 @default.
• W2137487130 hasConceptScore W2137487130C127413603 @default.

• next